AbbVie’s New Immunology Standard-Bearer Skyrizi Kneels to UCB’s Bimzelx in Psoriatic Arthritis

Why It Matters

The superiority of Bimzelx may shift prescribing patterns away from Skyrizi, impacting AbbVie’s revenue growth in a fast‑growing market. It also validates UCB’s strategic investments in autoimmune therapeutics.

Key Takeaways

• Bimzelx achieved 49.1% ACR50 vs 38.4% for Skyrizi.
• Skyrizi sales hit $17.56 billion in 2025, up 49.7% YoY.
• UCB spent $2 billion acquiring Candid Therapeutics.
• Minimal disease activity 43% with Bimzelx vs 39.9% with Skyrizi.
• AbbVie leveraged Skyrizi to offset Humira’s patent cliff.

Pulse Analysis

The Phase 3 head‑to‑head study provides clinicians with a rare direct comparison of two blockbuster biologics in psoriatic arthritis. By using the ACR50 endpoint, the trial demonstrated a statistically significant 10.7‑point advantage for Bimzelx, suggesting stronger joint symptom relief and potentially faster disease control. Such data are especially valuable in a therapeutic area where physicians balance efficacy, safety, and patient quality of life, and where head‑to‑head evidence can drive formulary decisions and insurance coverage.

Skyrizi’s commercial trajectory has been impressive, climbing from $11.7 billion in 2024 to $17.56 billion in 2025, a near‑50% year‑over‑year surge that helped AbbVie offset the steep decline of Humira after its patent cliff. However, the emergence of a competitor that can claim superior joint outcomes threatens to erode that momentum. With Humira now down to $4.54 billion, AbbVie’s reliance on Skyrizi to sustain growth is heightened, making the Bimzelx data a potential catalyst for market share reallocation and pricing negotiations.

UCB’s aggressive acquisition strategy underscores a broader industry trend of consolidating autoimmune pipelines. The $2 billion purchase of Candid Therapeutics and the $650 million Neurona deal expand UCB’s portfolio beyond Bimzelx, positioning the company to launch next‑generation therapies and diversify revenue streams. As larger pharma firms grapple with patent expiries and biosimilar competition, strategic M&A offers a pathway to maintain pipeline vigor and investor confidence, a dynamic that could reshape the competitive landscape of inflammatory disease treatment for years to come.